Custom service

Cyclic Peptide Drug Discovery

Discover cyclic peptide hits against a target of interest

Turnaround: 10–16 weeksTypical scale: 1 – 200 mg cyclic peptideChemistry options: mRNA-display and phage cyclic libraries; affinity selection with off-rate ranking; resynthesis and hit confirmation

Cyclic Peptide Drug Discovery supports programmes that discover cyclic peptide hits against a target of interest. In a typical engagement we plan the mRNA-display and phage cyclic libraries route first, confirm compatibility with affinity selection with off-rate ranking, and release confirmed hit set with affinity data on a 10–16 weeks schedule.

Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep mRNA-display and phage cyclic libraries as the primary option and hold affinity selection with off-rate ranking in reserve, so that scale-up never depends on an unproven step.

Targets intractable to small molecules

Macrocyclic hit matter for difficult PPIs

Targets without a usable assay

Cycles whose ring size is known to be geometrically uncloseable

Cyclic products are released against connectivity, not mass alone. MS/MS fragmentation confirms the ring closure, and where multiple topologies are possible the target isomer is isolated and its ratio reported. Protease-stability data are available as an add-on.

Service Highlights

  • MRNA-display and phage cyclic libraries as the default route, with affinity selection with off-rate ranking held as a proven fallback
  • Resynthesis and hit confirmation worked into the design where the application requires it
  • Cyclization strategy (head-to-tail, disulfide, lactam, thioether) chosen from a feasibility screen, not fixed by habit
  • Analytical confirmation of every intermediate before the final release
  • Cyclic/linear and topological isomers separated and reported, with the target isomer identified by MS/MS
  • Confirmed hit set with affinity data delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Precursor design

    Linear precursor, cyclization sites and protecting strategy are designed around the Cyclic Peptide Drug Discovery ring size.

  2. Linear assembly

    The precursor chain is assembled with Fmoc chemistry and mRNA-display and phage cyclic libraries where relevant.

  3. Cyclization

    Ring closure is executed by affinity selection with off-rate ranking under screened dilution and activation conditions.

  4. Isomer separation

    RP-HPLC resolves cyclic/linear and topological isomers; the target isomer is collected.

  5. Characterization

    Connectivity, purity and identity are confirmed by MS/MS and HPLC against the specification.

  6. Release

    Confirmed hit set with affinity data is documented and released after QC sign-off.

Specifications & timeline

Turnaround
10–16 weeks
Typical scale
1 – 200 mg cyclic peptide
Chemistry options
mRNA-display and phage cyclic libraries; affinity selection with off-rate ranking; resynthesis and hit confirmation
Deliverable
Confirmed hit set with affinity data
QC package
HPLC purity, MS/MS connectivity proof, isomer ratio, DMSO solubility
Shipping
Ambient with desiccant; blue ice for sensitive motifs

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.